Nanogen Receives 510(k) Clearance for StatusFirst(TM) Congestive Heart Failure NT-proBNP Test

Mar 29, 2006, 00:00 ET from Nanogen, Inc.

    SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Nanogen, Inc.
 (Nasdaq:   NGEN), developer of advanced diagnostic products, announced today
 that it has received 510(k) clearance from the U.S. Food and Drug
 Administration (FDA) to market its StatusFirst(TM) CHF NT-proBNP EDTA plasma
 test to aid in the diagnosis of individuals suspected of having congestive
 heart failure (CHF).
     "This is the first 510(k) clearance earned by Nanogen and is a significant
 milestone," noted Howard C. Birndorf, chairman of the board and CEO of
 Nanogen.  "The StatusFirst CHF 510(k) plasma clearance will permit us to begin
 the commercial launch of our CHF test.  We will continue our development work
 to achieve clearance of the StatusFirst CHF whole blood test, which would
 significantly expand the potential market for our CHF product."
     The StatusFirst CHF product results from collaboration between Nanogen and
 Princeton BioMeditech Corporation (PBM), an established rapid diagnostic test
 manufacturer.  Nanogen and PBM have co-developed and will co-market the
 product.  PBM will manufacture the product under contract with Nanogen.  The
 StatusFirst CHF test is sold in conjunction with the DXpress reader, a
 qualitative and quantitative instrument supplied by PBM.
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose, and
 ultimately help treat disease.  The company's products include real-time PCR
 reagents, the NanoChip(R) electronic microarray platform and a line of
 reagents useful in rapid diagnostic tests.  Nanogen's ten years of pioneering
 research involving nanotechnology holds the promise of miniaturization and
 continues to be supported for its potential for diagnostic and biowarfare
 applications.  For additional information please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof. Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.